Search Results - "Shore, N.D"

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment by Stenzl, A., Szmulewitz, R.Z., Petrylak, D., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N.D., Gomez-Veiga, F., Rosbrook, B., Baron, B., Haas, G.P., Armstrong, A.

Get full text

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months by Bögemann, M.W.H., Shore, N.D., Tammela, T.L.J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M-A., Snapir, A., Sarapohja, T., Fizazi, K.

Get full text

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 by Taplin, M.E, Chi, K.N, Chu, F, Cochran, J, Edenfield, W.J, Antonarakis, E.S, Emmenegger, U, Heath, E.I, Hussain, A, Njar, V.C, Koletsky, A, Lipsitz, D, Nordquist, L, Pili, R, Rettig, M, Sartor, O, Shore, N.D, Marrinucci, D, Mamlouk, K, Montgomery, B

Get full text

P312 - Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guérin (BCG)– unresponsive High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC) by Gupta, S., Kulkarni, G., Necchi, A., Shore, N.D., Dave, H., Kapadia, E., Zhao, Q., Kamat, A.

Get full text

Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guérin (BCG)– unresponsive High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC) by Gupta, S., Kulkarni, G., Necchi, A., Shore, N.D., Dave, H., Kapadia, E., Zhao, Q., Kamat, A.

Get full text

Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS) by Fizazi, K., Luz, M., Ulys, A., Ortiz, J., Srinivasan, S., Kurland, E., Shore, N.D.

Get full text

Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C by Necchi, A., Shore, N.D., Gupta, S., Kulkarni, G., Dave, H., Kapadia, E., Zhao, Q., Kamat, A.

Get full text

A1193 - Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS) by Fizazi, K., Luz, M., Ulys, A., Ortiz, J., Srinivasan, S., Kurland, E., Shore, N.D.

Get full text

A0522 - Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C by Necchi, A., Shore, N.D., Gupta, S., Kulkarni, G., Dave, H., Kapadia, E., Zhao, Q., Kamat, A.

Get full text

1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study by Tombal, B., Goebell, P.J., Shore, N.D., George, D.J., Pinto, A., Sartor, O., Meltzer, J., Verholen, F., Schmall, A., Saad, F.

Get full text

Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist? by Shore, N.D

“…The last few years have seen considerable evolution in treatment options and therapeutic strategies for patients with castrate-resistant prostate cancer…”
Get full text

A0525 - Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303 by Necchi, A., Bedke, J., Galsky, M.D., Shore, N.D., Xylinas, E., Jia, C., Dubrovsky, L., Homet Moreno, B., Witjes, A.J.

Get full text

1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114) by Avitia, J.W., Bailen, J.L., Shore, N.D., Tutrone, R.F., Nordquist, L.T., Walling, J., Peterson, L., Schotzinger, R., Moore, W.R.

Get full text

1385P Transcriptome-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS) by Ross, A., Iwata, K.K., Elsouda, D., Hairston, J., Russell, D., Davicioni, E., Proudfoot, J.A., Shore, N.D., Cooperberg, M.R., Schaeffer, E.M.

Get full text

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis by De Giorgi, U., Freedland, S.J., Rannikko, A., Ramirez-Backhaus, M., Villers, A., Gleave, M., Tarazi, J., Tang, Y., Haas, G.P., Rosales, M., Shore, N.D.

Get full text

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis by De Giorgi, U., Freedland, S.J., Rannikko, A., Ramirez-Backhaus, M., Villers, A., Gleave, M., Tarazi, J., Tang, Y., Haas, G.P., Rosales, M., Shore, N.D.

Get full text

1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP) by Morgans, A.K., Gschwend, J.E., Shore, N.D., Ross, A., Feng, F., Hope, T., Trandafir, L., Le Berre, M-A., Kuss, I., Joensuu, H., Fizazi, K.

Get full text

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study by Petrylak, D.P., Shore, N.D., Bennamoun, M., Ratta, R., Piulats, J.M., Li, B., Schloss, C., Fizazi, K.

Get full text

645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC) by Agarwal, N., Azad, A.A., Mateo, J., Shore, N.D., Chakrabarti, J., Chen, H-C., Lanzalone, S., Niyazov, A., Saad, F.

Get full text

639TiP KEYNOTE-365 cohort I: Phase Ib/II study of platinum containing chemotherapy in combination with pembrolizumab and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE) by Shore, N.D., Kramer, G., Joshua, A.M., Li, X.T., Poehlein, C.H., Schloss, C., de Bono, J.S., Yu, E.

Get full text